RxDoctor Payments Data

David Ouyang, MD

Family Medicine · Cortland, NYNPI 1417937780

Payments from drug & device makers

$1,097in general payments, 2019–2025

Across 69 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$359
  • GSK$140
  • Novo Nordisk$130
  • Gilead$96
  • Sanofi-aventis U.S. LLC$76
  • Lilly USA, LLC$54
  • plus $241 from 10 others

What the payments were for

  • Food & beverage$1,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,097 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$113,647
Medicare patients
341
Services billed
1,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate41$155,970
EliquisApixaban644$151,881
OzempicSemaglutide67$80,261
TrulicityDulaglutide41$51,664
RybelsusSemaglutide38$49,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$38,769
MounjaroTirzepatide31$31,122
XareltoRivaroxaban75$30,417
Glatiramer Acetate11$27,169
AustedoDeutetrabenazine13$23,692
CopaxoneGlatiramer Acetate11$21,587
EntrestoSacubitril/Valsartan52$17,602
JardianceEmpagliflozin36$16,372
LinzessLinaclotide18$13,607
Combivent RespimatIpratropium/Albuterol Sulfate22$11,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$151,881644 claims
Novo NordiskOzempic, Rybelsus$130$130,260105 claims
Lilly USA, LLCTrulicity, Mounjaro$54$82,78672 claims
GSKTrelegy Ellipta$140$38,76951 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$12$38,70379 claims
NovartisEntresto$16$17,60252 claims
AbbVieLinzess$18$13,60718 claims
MerckJanuvia$13$8,02429 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$23$7,36830 claims
Smith+NephewSantyl$30$6,86621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Cortland

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →